THRB and neoplasm: Therefore, the primary aim of this study was to examine whether GW0742 (a TRα and TRβ antagonist) and celecoxib (a TRβ antagonist) reduce tumour cell viability and metabolic activity, simultaneously counteracting the proliferative effects of T3.